Arch. Dis. Child

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, K
Right arrow Articles by Greenough, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, K
Right arrow Articles by Greenough, A
Archives of Disease in Childhood Fetal and Neonatal Edition 2003;88:F2-F5
© 2003 Archives of Disease in Childhood Fetal and Neonatal Edition


REVIEW

Treatment of neonatal abstinence syndrome

K Johnson1, C Gerada2, A Greenough1

1 Children Nationwide Regional Neonatal Intensive Care Centre, Department of Child Health, King’s College Hospital, London SE5 9RS, UK
2 The Hurley Clinic, Kennington Lane, London SE11 4HJ, UK

Correspondence to:
Correspondence to:
Dr Johnson, Department of Child Health, 4th floor, Ruskin Wing, King’s College Hospital, London SE5 9RS, UK:
kathryn.2.johnson{at}kcl.ac.uk


ABSTRACT
Neonatal abstinence syndrome (NAS) is suffered by infants withdrawing from substances on which they have become physically dependent after in utero exposure. They may require prolonged treatment and spend weeks or even months in hospital. A wide range of drugs have been used to treat NAS. The efficacy of few, however, have been adequately investigated. Evidence suggests that opioids are the most appropriate, at least in infants exposed to diamorphine or methadone. In all "head to head" trials, diazepam has been shown to be ineffective. Morphine and methadone are currently the most commonly prescribed opioids to treat NAS, but randomised trials have not been undertaken to determine which is the more beneficial. Many infants with NAS have been exposed to multiple substances in utero. Further research is required into whether a single opiate or a multiple drug regimen is the best option for such patients.


Keywords: neonatal abstinence syndrome; drug abuse




This article has been cited by other articles:


Home page
PediatricsHome page
W. K. Kraft, E. Gibson, K. Dysart, V. S. Damle, J. L. LaRusso, J. S. Greenspan, D. E. Moody, K. Kaltenbach, and M. E. Ehrlich
Sublingual Buprenorphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Trial
Pediatrics, September 1, 2008; 122(3): e601 - e607.
[Abstract] [Full Text] [PDF]


Home page
The Journal of the Royal Society for the Promotion of HealthHome page
Z. Kassim and A. Greenough
Effects of substance abuse during pregnancy
The Journal of the Royal Society for the Promotion of Health, September 1, 2005; 125(5): 212 - 214.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2003 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health